LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13 and 14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event, organized through its Venezuelan operating subsidiary LATAMEDAI VE, aims to bring together students, faculty, and participants from systems engineering and healthcare-related academic communities, including pharmacy, dentistry, and laboratory sciences.
The conference will focus on practical applications of artificial intelligence and automation across medical and technical environments. LataMed AI will be represented by Dr. Kevin Rodan Levy, Chief Executive Officer, and Carlos Pena, Chief Financial Officer, who are expected to address the evolving role of AI in healthcare, systems engineering, digital infrastructure, and professional decision-making.
During the presentation, LataMed AI intends to discuss how AI-supported tools may assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making. The company also plans to examine how automation could support the organization, reliability, and efficiency of technology systems used in healthcare and other complex operating environments. A key emphasis will be on maintaining qualified professional oversight when implementing AI, reinforcing that LataMed AI's technologies are designed to enhance human capabilities and support informed decision-making, rather than replace the independent judgment of professionals.
Additional topics expected to be covered include the integration of AI and automation into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations for developing and deploying technology in healthcare settings. LataMed AI will also discuss the continued development of its healthcare technology ecosystem, highlighting the roles of CardioAI, PulmoAI, and NeuroAI within its broader strategy. These AI-supported platforms are being developed to assist in the evaluation and management of cardiovascular, pulmonary, and neurological health information, subject to continued development, testing, regulatory requirements, and commercial implementation.
“Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering,” said Dr. Kevin Rodan Levy. “Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America.”
Management believes that engagement with universities and educational institutions can help increase awareness of emerging healthcare technologies, encourage responsible discussion regarding AI, and strengthen relationships with future professionals in healthcare, engineering, laboratory, and technology fields. The company also views this participation as an opportunity to better understand the perspectives of students, educators, researchers, and technical professionals as it continues developing digital health and AI-supported solutions for the Latin American market.
This initiative aligns with LataMed AI's broader strategy of supporting education, professional collaboration, and the responsible adoption of digital healthcare infrastructure throughout the region. The company intends to continue evaluating opportunities to participate in academic, healthcare, and technology forums that align with its business and educational objectives.
Participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria. The event does not guarantee future research collaborations, employment arrangements, commercial relationships, technology adoption, regulatory authorization, revenue, or other financial benefits.
For additional information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
